Could the 'Love Hormone' help prevent dangerous low blood sugar in diabetes?
NCT ID NCT06881459
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether oxytocin, a natural hormone, can improve the body's ability to release glucagon during low blood sugar (hypoglycemia) in people with type 1 diabetes. Sixteen adults with type 1 diabetes received both oxytocin and a placebo on separate days to compare their glucagon responses. The goal was to understand if oxytocin could help protect against dangerously low blood sugar levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Oxytocin
What this could lead to
If oxytocin boosts glucagon during hypoglycemia, it could point toward a new way to prevent dangerous low blood sugar in type 1 diabetes.
What could go wrong
This is a very small, early-stage study with only 16 participants. The effect may be small or not clinically meaningful, and oxytocin may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, 2900, Denmark